We're pulling the screening verdict, quote snapshot, and company context now.
Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 3,650 full-time employees. The firm operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The firm has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The company has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The firm sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. Its wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
BarakFi combines that company context with filing-driven screening ratios, market-cap evidence, and live quote snapshots so you can review the stock through a Shariah-screening lens without losing the underlying business picture.
Index and universe context: Nifty 500 • Nifty MIDCAP 100.